About Biofire Diagnostics
Biofire Diagnostics is a Healthcare company based in Salt Lake City (United States) founded in 1990, and was acquired by Institut Merieux in December 2021. Molecular diagnostic solutions for genetic condition detection are provided. Biofire Diagnostics has raised $84 million across 6 funding rounds from investors including HHS, BioMerieux and 10X Capital. Its website biofiredx.com draws about 35 thousand monthly visits. Biofire Diagnostics offers products and services including BIOFIRE System, Respiratory Panel, and Gastrointestinal Panel. Its focus areas include Life Sciences, Clinical Genomics, Amplification Based and PCR. Its legal entity is BIOFIRE DIAGNOSTICS, INC. Its competitors include ChromaCode, Inflammatix and Visby Medical; 3 of its 3 listed competitors have raised funding.
Company details
Biofire Diagnostics was founded in 1990 and is headquartered in Salt Lake City, United States. Operations center on the molecular diagnostics sector, where new assays are developed for the proprietary FilmArray System, a multiplex PCR platform. Panels offered include Respiratory (RP), Blood Culture Identification (BCID), Gastrointestinal (GI), and MeningitisEncephalitis (ME) tests for pathogen detection.
- Headquarters Salt Lake City, United States
- Stage Acquired
- SectorsHealthcare
- Website biofiredx.com
- Social LinkedIn X Facebook YouTube
- Acquired by Institut Merieux (Dec 2021)
- Legal Name Biofire Diagnostics, Inc.
- Total Equity Funding$84M (USD)
in 6 rounds
- Latest Funding Round$14M (USD), Series A
Nov 2022
- InvestorsHHS
& 10 more
- Acquired by
Products & Services of Biofire Diagnostics
Biofire Diagnostics offers a comprehensive portfolio of products and services, including BIOFIRE System, Respiratory Panel, and Gastrointestinal Panel.
Multiplex PCR system for rapid infectious disease testing.
Detects viruses and bacteria in respiratory samples.
Identifies pathogens in gastrointestinal infections.
Apps and channels of Biofire Diagnostics
its YouTube channel bioMérieux USA has 1.71K subscribers and 30 videos.
Videos from Biofire Diagnostics
The most watched videos on Biofire Diagnostics's YouTube channel, bioMérieux USA (1.71K subscribers). Click a video to play it here.
More on bioMérieux USA.
Funding Insights of Biofire Diagnostics
Biofire Diagnostics has successfully raised a total of $84M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $14 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $84M
- Total Rounds 6
- Last Round Series A — $14M
- First Round $25M
(Sep 2012)
- Investors Count 9
All 6 funding rounds of Biofire Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2022 | $14M | Series A | – | Founders Fund | |
| Mar 2015 | $6.27M | Grant | – | – | |
| Aug 2014 | $168,000 | Grant | – | – | |
| Jul 2013 | $3.57M | Grant | – | – | |
| May 2013 | $45M | Private Equity Round | – | – | |
| Sep 2012 | $25M | Private Equity Round | – | – |
11 investors in total: 11 institutional.
Investors in Biofire Diagnostics
Biofire Diagnostics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, BioMerieux and 10X Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments in technology and defense sectors. | foundersfund.com | |||
Access to private investment strategies is provided for institutional investors. | 2004 | 10xcapital.com | New York, United States | |
Venture capital investing with a focus on diversity and inclusion in the ecosystem. | gaingels.com | |||
Early-stage technology companies receive venture capital investments. | draper.vc | San Mateo, United States | ||
Seed and early-stage tech investments in the US are targeted. | structure.vc | San Francisco, United States | ||
Early-stage tech investments are made in US-based companies. | serviceprovidercapital.com | Golden, United States | ||
Global private equity investments are managed by the firm. | athyrium.com | New York, United States | ||
Security services are provided by Gavin de Becker and Associates. | 1978 | gdba.com | Glendale, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Developer of diagnostics devices for multiple health purposes | 1963 | biomerieux.com |
Investor details for Biofire Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Biofire Diagnostics
5 dated milestones of Biofire Diagnostics across 32 years, from founding to its latest funding, stage changes and deals.
- Founded Biofire Diagnostics is founded.
- Funding First funding round of $25.0M.
- Exit Acquired by BioMerieux.
- Exit Acquired by Institut Merieux.
- Funding Latest funding round, Series A, of $14.0M.
Competitors of Biofire Diagnostics
Biofire Diagnostics has 3 listed competitors in our database, 3 of them funded. They include ChromaCode, Inflammatix and Visby Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| chromacode.com | 2012 | Carlsbad, United States | $95.02M | 46 | Digital molecular biology analytics are developed for disease management. | |
| inflammatix.com | 2016 | San Francisco, United States | $191.47M | 54 | Provider of diagnostic solutions for systemic infections | |
| visbymedical.com | 2010 | San Jose, United States | $386.33M | 251 | Portable PCR diagnostics for infectious diseases are developed. |
Detailed competitors of Biofire Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Biofire Diagnostics
The website of Biofire Diagnostics (biofiredx.com) receives about 35.2K visits a month.
- Monthly visits35.2K
▲ 40.6% vs previous month
Websites whose visitors overlap most with Biofire Diagnostics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
recruitment.biomerieux.com | recruitment.biomerieux.com | 100% | – | ||
| nanosphere.us | 70% | 1.2K | #12,469,478 | View details | |
biofireinc.com | biofireinc.com | 67% | – | ||
| smartgun.com | 66% | 10.9K | #2,101,481 | View details | |
| qiagen.com | 48% | 458.2K | #105,023 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Biofire Diagnostics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biofire Diagnostics
Complete news archive for Biofire Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biofire Diagnostics
Biofire Diagnostics was founded in 1990 and raised its 1st funding round 22 years after it was founded.
Biofire Diagnostics is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
Biofire Diagnostics is a funded company, having raised a total of $84M across 6 funding rounds to date. The company's 1st funding round was a Private Equity Round of $25M, raised on Sep 2012.
Biofire Diagnostics was founded in 1990 and is headquartered in Salt Lake City, United States. Operations center on the molecular diagnostics sector, where new assays are developed for the proprietary FilmArray System, a multiplex PCR platform. Panels offered include Respiratory (RP), Blood Culture Identification (BCID), Gastrointestinal (GI), and MeningitisEncephalitis (ME) tests for pathogen detection.
Biofire Diagnostics's top competitors include ChromaCode, Visby Medical and Inflammatix.
Biofire Diagnostics offers BIOFIRE System, Respiratory Panel, and Gastrointestinal Panel.
Biofire Diagnostics has 11 investors. Key investors include HHS, BioMerieux, 10X Capital, Institut Mérieux, and Gavin de Becker and Associates.
Biofire Diagnostics operates through Biofire Diagnostics, Inc..
Yes. Biofire Diagnostics was acquired by Institut Merieux in December 2021.